# US 2021/0261653 A1 · Immunoglobulin variable domains

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2021/0261653 A1
- Document ID: US20210261653A1
- Status: Published application
- Kind: A1
- Application number: 17/215,121
- Filed: 2021-03-29
- Published: 2021-08-26
- Earliest claimed: 2014-05-16
- Assignees: Ablynx N.V.
- Applicants: Ablynx N.V.
- Inventors: Marie-Ange Buyse; Carlo Boutton
- Web page: https://patentgrep.com/patent/US20210261653A1

## CPC

- C07K 16/18: against material from animals or humans
- A61P 37/02: Immunomodulators
- C07K 16/00: Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K 16/24: against cytokines, lymphokines or interferons
- C07K 16/241: {Tumor Necrosis Factors}
- C07K 16/244: {Interleukins [IL]}
- C07K 16/28: against receptors, cell surface antigens or cell surface determinants
- C07K 16/2863: {against receptors for growth factors, growth regulators}
- C07K 16/2866: {against receptors for cytokines, lymphokines, interferons}
- C07K 16/2875: {against the NGF/TNF superfamily, e.g. CD70, CD95L, CD153, CD154 (against NGF C07K16/22, against TNF C07K16/241)}
- C07K 16/30: from tumour cells
- C07K 16/32: against translation products of oncogenes
- C07K 16/42: against immunoglobulins
- C07K 16/4291: {against IgE}
- C07K 2317/22: from camelids, e.g. camel, llama or dromedary
- C07K 2317/31: multispecific
- C07K 2317/35: Valency
- C07K 2317/565: Complementarity determining region [CDR]
- C07K 2317/567: Framework region [FR]
- C07K 2317/569: Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®
- C07K 2317/76: Antagonist effect on antigen, e.g. neutralization or inhibition of binding
- C07K 2319/00: Fusion polypeptide
- C07K 2319/31: fusions, other than Fc, for prolonged plasma life, e.g. albumin
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

VH domain, in which: (i) the amino acid residue at position 112 is one of K or Q; and/or (ii) the amino acid residue at position 89 is T; and/or (iii) the amino acid residue at position 89 is L and the amino acid residue at position 110 is one of K or Q; and (iv) in each of cases (i) to (iii), the amino acid at position 11 is preferably V; and in which said VH domain contains a C-terminal extension (X)n, in which n is 1 to 10, preferably 1 to 5, such as 1, 2, 3, 4 or 5 (and preferably 1 or 2, such as 1); and each X is an (preferably naturally occurring) amino acid residue that is independently chosen, and preferably independently chosen from the group consisting of alanine (A), glycine (G), valine (V), leucine (L) or isoleucine (I).

## Claims

### Claim at position 1

-72. (canceled)

### Claim 73

A polypeptide comprising a first immunoglobulin single variable domain (ISVD) that specifically binds to human serum albumin and a second ISVD that specifically binds to a therapeutic target, wherein the second ISVD is at the C-terminal end of the polypeptide and comprises an amino acid V at Kabat position 11 and an amino acid L at Kabat position 89, and wherein the polypeptide has reduced binding to its C-terminal region by pre-existing antibodies found in blood or serum samples obtain from human subjects.

### Claim 74 (depends on 73)

The polypeptide of claim 73, wherein the second ISVD comprises a C-terminal extension (X)n, in which n is 1 to 10, wherein each X is an independently chosen amino acid.

### Claim 75 (depends on 73)

The polypeptide of claim 73, wherein the second ISVD comprises a C-terminal end comprising an amino acid sequence selected from the group consisting of: VTVSS (SEQ ID NO:76), VTVSS(X)n (SEQ ID NO:77), VTVKS (SEQ ID NO:1), VTVKS(X)n (SEQ ID NO:21), VTVQS (SEQ ID NO:2), VTVQS(X)n (SEQ ID NO:22), VKVSS (SEQ ID NO: 95), VKVSS(X)n (SEQ ID NO:97), VQVSS (SEQ ID NO: 96), VQVSS(X)n (SEQ ID NO: 98), VZVZS (SEQ ID NO: 107, in which each amino acid residue Z is independently K or Q) or VZVZS(X)n (SEQ ID NO:108, in which each amino acid residue Z is independently K or Q), in which n is 1 to 10; and wherein each X is an independently chosen amino acid.

### Claim 76 (depends on 73)

The polypeptide of claim 73, wherein the second ISVD comprises a C-terminal end comprising an amino acid sequence selected from the group consisting of: VTVSS (SEQ ID NO:76), VKVSS (SEQ ID NO: 95), VQVSS (SEQ ID NO: 96), VTVSS(X)n (SEQ ID NO:77), VKVSS(X)n (SEQ ID NO:97) or VQVSS(X)n (SEQ ID NO: 98), in which n is 1 to 10, and wherein each X is an independently chosen amino acid.

### Claim 77 (depends on 73)

The polypeptide of claim 73, wherein the second ISVD comprises a C-terminal end comprising an amino acid sequence selected from the group consisting of VTVSS (SEQ ID NO:76) or VTVSS(X)n (SEQ ID NO:77), in which n is 1 to 10, wherein each X is an independently chosen amino acid.

### Claim 78 (depends on 73)

The polypeptide of claim 73, wherein the first ISVD comprises a CDR1, CDR2, and CDR3, in which CDR1 comprises the amino acid sequence SFGMS (SEQ ID NO:41); CDR2 comprises the amino acid sequence SISGSGSDTLYADSVKG (SEQ ID NO:42); and CDR3 comprises the amino acid sequence GGSLSR (SEQ ID NO:43).

### Claim 79 (depends on 73)

The polypeptide of claim 73, wherein the first ISVD is Alb-1 (SEQ ID NO: 767), Alb-8 (SEQ ID NO:46) or Alb-23 (SEQ ID NO:61).

### Claim 80 (depends on 73)

The polypeptide of claim 73, wherein the first ISVD comprises an amino acid V at Kabat position 11 and an amino acid L at Kabat position 89.

### Claim 81 (depends on 80)

The polypeptide of claim 80, wherein the first ISVD further comprises:
an amino acid selected from the group consisting of A and P at Kabat position 14;
an amino acid selected from the group consisting of A and P at Kabat position 41;
an amino acid selected from the group consisting of Q and L at Kabat position 108;
an amino acid selected from the group consisting of T and Q at position 110; and
an amino acid selected from the group consisting of S, K, and Q at Kabat position 112.

### Claim 82 (depends on 81)

The polypeptide of claim 81, wherein the first ISVD further comprises:
an amino acid T at Kabat position 110 and an amino acid S at Kabat position 112;
an amino acid selected from the group consisting of K and Q at Kabat position 110 and an amino acid S at Kabat position 112; or
an amino acid T at Kabat position 110 and an amino acid selected from the group consisting of K and Q at Kabat position 112.

### Claim 83 (depends on 82)

The polypeptide of claim 82, wherein the first ISVD has at least 90% sequence identity with at least one of Alb-1 (SEQ ID NO: 767), Alb-8 (SEQ ID NO:46) or Alb-23 (SEQ ID NO:61).

### Claim 84 (depends on 82)

The polypeptide of claim 82, wherein the first ISVD comprises a CDR1, CDR2, and CDR3, in which CDR1 comprises the amino acid sequence SFGMS (SEQ ID NO:41); CDR2 comprises the amino acid sequence SISGSGSDTLYADSVKG (SEQ ID NO:42); and CDR3 comprises the amino acid sequence GGSLSR (SEQ ID NO:43).

### Claim 85 (depends on 73)

The polypeptide of claim 73, wherein the first ISVD is a VHH domain, a humanized VHH domain, or a camelized VH domain.

### Claim 86 (depends on 73)

The polypeptide of claim 73, wherein the second ISVD further comprises:
an amino acid selected from the group consisting of A and P at Kabat position 14;
an amino acid selected from the group consisting of A and P at Kabat position 41;
an amino acid selected from the group consisting of Q and L at Kabat position 108;
an amino acid selected from the group consisting of T, K and Q at position 110; and
an amino acid selected from the group consisting of S, K, and Q at Kabat position 112.

### Claim 87 (depends on 86)

The polypeptide of claim 86, wherein the second ISVD further comprises:
an amino acid T at Kabat position 110 and an amino acid S at Kabat position 112;
an amino acid selected from the group consisting of K and Q at Kabat position 110 and an amino acid S at Kabat position 112; or
an amino acid T at Kabat position 110 and an amino acid selected from the group consisting of K and Q at Kabat position 112.

### Claim 88 (depends on 73)

The polypeptide of claim 73, wherein the second ISVD is a VHH domain, a humanized VHH domain, or a camelized VH domain.

### Claim 89 (depends on 73)

The polypeptide of claim 73, wherein the first and second ISVDs are connected directly or indirectly via a suitable linker.

### Claim 90 (depends on 73)

A nucleic acid encoding a polypeptide according to claim 73.

### Claim 91 (depends on 73)

A composition comprising a polypeptide according to claim 73.

### Claim 92 (depends on 91)

The composition of claim 91, further comprising at least one pharmaceutically acceptable carrier, diluent or excipient.
